Patients with HER2-low metastatic breast cancer are a historically overlooked group, but a phase 3 trial reveals trastuzumab deruxtecan as a new treatment option that prolongs survival.

中文翻译：

---

HER2低乳腺癌急需的治疗方法

HER2-low 转移性乳腺癌患者在历史上是一个被忽视的群体，但一项 3 期试验显示曲妥珠单抗 deruxtecan 是一种可延长生存期的新治疗选择。